Eli Lilly & Co (LLY) Earnings Date & Reports

Key Takeaways

• Revenue surged 48% year-over-year to $22.97 billion, crushing the consensus estimate of approximately $20.26 billion by a wide margin.
• Non-GAAP earnings per share (EPS) reached $8.38, up 33% from the prior-year period and far exceeding analyst expectations of roughly $6.01, with reported (GAAP) EPS coming in at $7.94.
• Mounjaro and Zepbound delivered a combined $14.9 billion in quarterly revenue, with Mounjaro alone soaring 91% year-over-year to $9.94 billion and Zepbound climbing 46% to $4.93 billion.
• Full-year 2026 revenue guidance was raised to a range of $85 billion to $87 billion, up from the prior outlook of $82 billion to $85 billion, while non-GAAP EPS guidance was narrowed to $35.50–$36.50.
• The quarter included $3.03 per share in acquired in-process research and development (IPR&D) charges tied to multiple acquisitions, which weighed on reported profitability but underscored the company's aggressive investment in its pipeline.
• Shares jumped more than 5% in premarket trading and maintained gains through the regular session, reflecting broad investor enthusiasm for the magnitude of the revenue beat.

Earnings Context and Why It Matters

Eli Lilly's second-quarter 2026 earnings report, released on August 5 before the market opened, represents a pivotal moment for one of the world's most valuable pharmaceutical companies. With a market capitalization hovering near $1 trillion, Lilly has become the defining name in the global obesity and diabetes treatment market. This quarter was particularly significant because it marked the first full quarter of sales for Foundayo (orforglipron), the company's newly launched oral GLP-1 (glucagon-like peptide-1) pill, and arrived during a period of aggressive dealmaking that saw Lilly complete four major acquisitions. Coming off a strong Q1 2026 in which the company also beat expectations handily, investors were watching closely to see whether the momentum in the company's incretin franchise — the drug class that includes Mounjaro and Zepbound — could be sustained amid growing competition and pricing pressure.

Reported Results

Eli Lilly reported second-quarter worldwide revenue of $22.97 billion, a 48% increase compared with $15.56 billion in the same period last year. The result sailed past the Zacks Consensus Estimate of $20.26 billion and other analyst projections that clustered near $20.7 billion. Volume growth of 60% was the primary driver, more than offsetting a 13% decline in net realized prices globally.

On the bottom line, GAAP net income rose 25% to $7.10 billion, producing reported EPS of $7.94. On a non-GAAP basis, which excludes items such as amortization of intangible assets and certain acquisition-related costs, EPS came in at $8.38 — a 33% year-over-year increase that comprehensively beat the consensus forecast of roughly $6.01. Both reported and adjusted figures included $3.03 per share in acquired IPR&D charges stemming from the quarter's business development activity, compared with just $0.14 in Q2 2025.

Mounjaro, Lilly's diabetes treatment, was the standout performer, generating $9.94 billion in global revenue — a 91% surge from the prior-year quarter. U.S. Mounjaro sales reached $4.8 billion, while international sales hit $5.2 billion, boosted by the drug's inclusion on China's National Reimbursement Drug List. Zepbound, the obesity-focused counterpart, delivered $4.93 billion in U.S. revenue, up 46% year-over-year. Foundayo contributed $98 million in its first partial quarter on the market following its April launch.

Gross margin as a percentage of revenue expanded to 86.3% on a non-GAAP basis (85.8% on a reported basis), up 1.3 percentage points from the prior year, driven by improved production costs and favorable product mix. Operating expenses rose, with R&D spending increasing 14% to $3.8 billion as Lilly funded more than 40 active Phase 3 programs.

Among other products, Jardiance revenue rose 79% to $1.23 billion, benefiting from a $250 million sales-based milestone payment. Trulicity grew 12% to $1.22 billion, while Verzenio slipped 1% to $1.47 billion. Newer drugs — including Jaypirca (up 56%), Ebglyss (up 131%), Omvoh (up 36%), and Kisunla at $167 million — demonstrated broadening portfolio strength.

AI Screener

For investors looking to identify opportunities across the pharmaceutical sector and beyond, Tickeron's AI Screener offers a powerful, AI-driven stock and ETF discovery platform. The AI Screener enables traders and investors to filter thousands of equities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated trading signals. Whether scanning for breakout candidates, tracking sector momentum, or identifying stocks exhibiting specific fundamental and technical profiles, the screener streamlines what would otherwise be a time-intensive manual process. For those monitoring earnings-driven moves like Eli Lilly's Q2 report, the AI Screener can help surface related trade ideas and emerging trends across the healthcare landscape.

Market Reaction and Investor Sentiment

Eli Lilly shares rose more than 5% in premarket trading on August 5 and maintained solid gains throughout the regular session, closing up approximately 2.4% to 2.6% near $1,147. Some intraday readings showed the stock climbing as much as 8% to roughly $1,209, pushing Lilly's market capitalization back above $1.1 trillion. The positive reaction reflected investor relief and enthusiasm that the company not only delivered a substantial top-line beat but also raised full-year guidance for the second time in 2026. The revenue beat of more than $2.5 billion relative to consensus overshadowed any concern about the acquired IPR&D charges that trimmed reported EPS. The stock's move also broke a five-day losing streak and reclaimed the 50-day moving average, signaling that the market viewed the print as a reaffirmation of Lilly's dominant competitive positioning in the cardiometabolic space.

Forward Outlook and Key Factors to Monitor

Following this strong quarter, several forward-looking themes will shape how investors assess Eli Lilly over the remainder of 2026 and into 2027.

The most important near-term catalyst is the commercial trajectory of Foundayo (orforglipron), Lilly's once-daily oral GLP-1 pill. With $98 million in first-quarter sales falling slightly short of some analyst expectations, the rate of prescription adoption in the coming quarters will be closely scrutinized — especially as rival Novo Nordisk ramps up its own oral Wegovy offering, which generated roughly $500 million in the same period. Lilly management has indicated plans to launch Foundayo in most international markets during 2027, setting up another potential growth wave.

Equally significant is the retatrutide program. With all Phase 3 clinical data now in hand for obesity, obstructive sleep apnea, and knee osteoarthritis pain, Lilly plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027. Retatrutide, a triple-hormone receptor agonist, is widely viewed as Lilly's next-generation successor to tirzepatide (the active ingredient in Mounjaro and Zepbound), and positive regulatory momentum could meaningfully extend the company's leadership in metabolic medicine.

Investors should also monitor the pace of pricing pressure. Realized prices declined 13% globally and 36% in international markets during Q2, driven in part by Mounjaro's addition to China's reimbursement formulary. While volume growth has more than compensated so far, sustained price erosion in key markets could eventually pressure margins, particularly as competition intensifies and payers gain leverage.

Finally, Lilly's acquisition spree deserves continued attention. With more than $20 billion in deals announced this year — spanning oncology, neuroscience, gene editing, and infectious disease — the company is betting heavily that strategic M&A (mergers and acquisitions) will diversify its revenue base beyond incretin drugs. Integration risks, pipeline setbacks, and the cumulative drag of acquisition-related charges on reported earnings are all factors that could temper near-term enthusiasm even as the core business delivers exceptional growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations